Company news
Dyadic International, Inc. (NASDAQ:DYAI) news
Every Dyadic International, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Dyadic International, Inc. Secures $2.9 Million Through Registered Direct Offering and Concurrent Private Placement
August 13, 2026
Dyadic Announces Second Quarter 2026 Financial Results Accelerating Commercialization Momentum Across Key Business Areas
August 12, 2026
Dyadic Expands Commercial Non-Animal Dairy Pipeline Through New Strategic Development Agreement
August 4, 2026
Dyadic to Report Q2 2026 Financial Results and Host Conference Call on Wednesday August 12, 2026
August 3, 2026
Dyadic Develops Stable C1 Cell Lines and Produces Purified Scripps-Designed Bundibugyo Ebola Antigens from Plasmids in Approximately 15 Days
July 28, 2026
Dyadic Announces Continued Listing on the Nasdaq Capital Market
July 24, 2026
Dyadic Expands Bio industrial Pipeline with New Proprietary Industrial Enzyme Program
July 16, 2026
Global Collaborations Continue to Validate Dyadic’s C1 Platform and Expands Commercial Potential
July 7, 2026
Dyadic Expands IP Protection and Business Development Activities in Japan
June 29, 2026
An Interview with the President & COO: How Dyadic is Commercializing Its Protein Platform Across Multi-Billion-Dollar Markets
June 22, 2026
Dyadic Highlights Accelerated Interest in C1 Biomanufacturing Platform Amid Ebola Preparedness Activities and Growing Commercial Adoption
June 15, 2026
Dyadic and Scripps Research Collaborate on Rapid-Response Hantavirus Antibody and Vaccine Development
May 28, 2026
Dyadic to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
May 21, 2026
Skyline Corporate Communications Group, LLC Announces Dyadic Applied BioSolutions to Deliver a Live Presentation at the Skyline Signature...
May 21, 2026
Dyadic Applied BioSolutions Announces Participation in Sidoti Virtual Investor Conference
May 19, 2026
Dyadic to Report Q1 2026 Financial Results and Host Conference Call on Wednesday May 13, 2026
April 29, 2026
Dyadic Announces 2025 Financial Results and Highlights Recent Company Progress
March 25, 2026
Dyadic Applied BioSolutions Announces Commercial Distribution Partnership with IBT Bioservices
March 16, 2026
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing
March 13, 2026
Dyadic to Report 2025 Full Year Financial Results and Host Conference Call on Wednesday, March 25, 2026
March 11, 2026
Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th
March 10, 2026
Dyadic and Fermbox Bio Launch First Product Under Expanded Collaboration: Animal-Origin-Free Recombinant DNase I (RNase-Free)
March 4, 2026
Dyadic Applied BioSolutions and Inzymes ApS Announce Planned 2026 Commercialization of Non-Animal Dairy Enzyme Following Achievement of D...
March 2, 2026
Dyadic Applied BioSolutions and Proliant Health & Biologicals Announce Commercial Launch of Recombinant Human Albumin
February 17, 2026
Dyadic and Fermbox Bio Expand Strategic Collaboration to Accelerate Commercialization of Animal-Free Proteins and Enzymes Across Life Sci...
December 17, 2025
Dyadic Applied BioSolutions Establishes Commercial Partnership to Accelerate Adoption of Dyadic’s Recombinant Growth Factors and Media Pr...
December 15, 2025
Dyadic and BRIG BIO Sign Development & Commercialization Agreement to Bring Animal-Free Bovine Alpha-Lactalbumin to Global Nutrition Markets
December 1, 2025
Dyadic Announces Third Quarter 2025 Financial Results and Highlights Strategic Progress
November 12, 2025
ERS Genomics and Dyadic Applied BioSolutions Sign CRISPR/Cas9 License Agreement
November 10, 2025
Dyadic Applied BioSolutions Expands Genetic Engineering Capabilities Through CRISPR/Cas9 Commercial License with ERS Genomics
November 10, 2025
Dyadic to Report Third Quarter 2025 Financial Results on Wednesday, November 12, 2025
October 29, 2025
Dyadic Applied BioSolutions Announces Milestone Achievements and Recent Company Developments
October 6, 2025
Dyadic to Present at Investor Conferences and BPI East
September 4, 2025
Dyadic Reports Second Quarter 2025 Financial Results and Highlights of Recent Company Progress
August 13, 2025
Dyadic to Report Second Quarter 2025 Financial Results on Wednesday, August 13, 2025
August 5, 2025
UPDATE: Dyadic International, Inc. Announces Pricing of Public Offering of 6,052,000 Shares of Common Stock
July 31, 2025
Dyadic International, Inc. Announces Pricing of Public Offering of 6,052,000 Shares of Common Stock
July 31, 2025
Dyadic International, Inc. Announces Proposed Public Offering of Common Stock
July 30, 2025
Dyadic International, Inc. Announces Strategic Rebrand to Dyadic Applied BioSolutions
July 2, 2025
Dyadic Announces Leadership Change as Part of Ongoing Strategic Shift to Focus on High Demand Ancillary Proteins for Life Sciences, Nutri...
June 2, 2025
Dyadic Reports First Quarter 2025 Financial Results and Highlights of Recent Company Progress
May 14, 2025
Dyadic to Report First Quarter 2025 Financial Results on Wednesday, May 14, 2025
May 1, 2025
Dyadic to Present at World Vaccine Congress | Washington
April 16, 2025
Dyadic Reports 2024 Year-End Financial Results and Business Updates
March 26, 2025
Dyadic Announces Funding Award from CEPI to Use C1 to Accelerate Development of Protein-Based Vaccines
March 20, 2025
Dyadic to Report 2024 Full Year Financial Results and Host Conference call on Wednesday, March 26, 2025
March 12, 2025
Dyadic to Attend Multiple Industry Events in March
March 6, 2025
Dyadic Provides Business Update; Dyadic to Attend the 43rd Annual J.P. Morgan Healthcare Conference
January 6, 2025
Dyadic Receives $3 Million Grant to Develop Cost-Effective Monoclonal Antibodies for RSV and Malaria Using C1 Platform Technology
November 21, 2024
Dyadic Announces Third Quarter 2024 Financial Results and Strategic Progress Across Key Markets
November 12, 2024